f7ddd671-b2ba-4952-918b-07ae0ea84263
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.300
- CHOLESTEROL_HOMEOSTASIS+0.200
- E2F_TARGETS+0.200
- G2M_CHECKPOINT+0.200
- HEME_METABOLISM+0.200
- MYC_TARGETS_V1+0.200
- OXIDATIVE_PHOSPHORYLATION+0.200
- PEROXISOME+0.200
- ADIPOGENESIS+0.100
- BILE_ACID_METABOLISM+0.100
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.500
- IL6_JAK_STAT3_SIGNALING-0.500
- INTERFERON_GAMMA_RESPONSE-0.500
- INFLAMMATORY_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.400
- ANGIOGENESIS-0.300
- COMPLEMENT-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- KRAS_SIGNALING_UP-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclc2008_S40.txt | — | cohortSC | 0.869 |
| 2 | 444cc5d2-e345-43ca-8289-193072077eca | — | — | 0.853 |
| 3 | SAMN03290953 | — | — | 0.852 |
| 4 | s0112311 | — | — | 0.851 |
| 5 | TCGA-B6-A0IB-01A-11R-A034-07 | — | B | 0.849 |
| 6 | SRR12202419 | — | — | 0.847 |
| 7 | TCGA-E2-A14T-01A-11R-A115-07 | — | B | 0.846 |
| 8 | SAMN03290941 | — | — | 0.844 |
| 9 | f8d9864e-e148-4e60-9d9d-3df2897050cd | — | — | 0.842 |
| 10 | TCGA-E2-A1IE-01A-11R-A13Q-07 | — | B | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.200 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.200 | Remibrutinib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.100 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.100 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.100 | Inavolisib | — uncovered |